Hematology — a weekly podcast briefing of the most significant peer-reviewed hematology literature, synthesized from PubMed and delivered as ~10-minute audio. For practicing physicians. Generated by AudioScholar at audioscholar.cc. India edition.
Editor's Pick: Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial (The Lancet, 2026)
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning new oral and targeted therapies in non-malignant hematology, a fresh look at treatment strategy in the myeloproliferative neoplasms, and the risks that come with…
This week's papers:
1. Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial. — The Lancet 2026
2. Clinical Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. — American Journal of Hematology 2026
3. Combination of Thrombopoietin Receptor Agonists and Rituximab in Relapsed/Refractory Immune Thrombocytopenia: A Multicenter Real-World Study. — Journal of Thrombosis and Haemostasis 2026
4. Emicizumab Prophylaxis in People with Haemophilia A: Summary of Over 13 Years of Safety Data on Thromboembolic Events and Thrombotic Microangiopathy. — Journal of Thrombosis and Haemostasis 2026
5. Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial. — Blood Cancer Journal 2026
6. High Initial Dose and Accelerated vs. Slow Titration Ropeginterferon Alfa-2b for Polycythemia Vera: A Meta-Analysis. — Blood Advances 2026
7. New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification. — American Journal of Hematology 2026
8. Hematopoietic Cell Transplantation Outcomes in the Era of Post-Transplant Cyclophosphamide: Comprehensive Donor Analysis. — Blood Advances 2026
9. Molecular Underpinnings and Prevalence of Donor Cell-Derived Hematologic Neoplasms among Spanish Transplantation Centers. — Blood 2026
10. Temporal trends in infectious risk among multiple myeloma patients treated with daratumumab: A meta-analysis. — British Journal of Haematology 2026
Listen at https://audioscholar.cc/episode/fnu3j7zm6j
21 Oct 2026
This Week in Hematology — Oct 21, 2026
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning chemotherapy-free and res…
This week's papers:
1. Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL. — New England Journal of Medicine 2026
2. Flow MRD pre-blinatumomab consolidation, despite subsequent clearance, is associated with inferior survival in Ph+ B-ALL. — Blood Advances 2026
3. A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years. — Blood 2026
4. American Society of Hematology 2026 Guidelines for the Management of Myelofibrosis in Adults. — Blood Advances 2026
5. Incidence of thrombosis and bleeding in patients with JAK2- positive myeloproliferative neoplasms receiving low-dose aspirin: a systematic review and meta-anal… — Journal of Thrombosis and Haemostasis 2026
6. National Alliance of Sickle Cell Disease Consensus Recommendations for Gene Therapy Implementation. — Blood Advances 2026
7. Sustained improvement in sickle cell cardiomyopathy after haematopoietic stem cell transplantation is superior to that with disease-modifying therapy. — British Journal of Haematology 2026
8. Cases of High-Titer Inhibitor Formation After AAV Gene Therapy for Hemophilia A. — Blood 2026
9. Clinical characteristics and outcome of a cohort of CLL patients with BTK T474 gatekeeper mutation. — Blood Advances 2026
10. Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy. — Nature Medicine 2026
Listen at https://audioscholar.cc/episode/jemyngahqs
14 Oct 2026
This Week in Hematology — Oct 14, 2026
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Hematology. This week we're covering 10 notable papers spanning frontline therapy and res…
This week's papers:
1. Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA… — Leukemia 2026
2. Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients tr… — Leukemia 2026
3. Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for… — Haematologica 2026
4. Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy. — Blood Advances 2026
5. Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse and improved survival. — Blood 2026
6. Choice of a different donor reduces relapse risk after second allogeneic SCT for MDS. — Blood 2026
7. Allogeneic stem cell transplantation in aggressive Adult T cell leukemia/lymphoma: a prospective multicenter study. — Blood Advances 2026
8. MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma. — Leukemia 2026
9. Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy. — American Journal of Hematology 2026
10. Molecular surveillance of aggressive large B-cell lymphoma using circulating tumor DNA duplexes. — Haematologica 2026
Listen at https://audioscholar.cc/episode/e6j7mbj2m8
Contact AudioScholar Hematology Weekly (India)
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of AudioScholar Hematology Weekly (India)?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
